Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (381-390 of 578) with videos related to

Pageof 58
Sort By:
The Oncologist|September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast CancerKathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph nodeAnneleen Reynders, Olivier Brouckaert, Ann Smeets, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2020
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group surveyStefano Greggi, Francesca Falcone, Cono Scaffa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2023
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialRenaud Sabatier, Frédérique Rousseau, Florence Joly, et al.
The Lancet. Oncology|May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trialIgnace Vergote, Giovanni Scambia, David M O'Malley, et al.
Computational and Structural Biotechnology Journal|May 4, 2019
Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian CancerAnastasia Meshcheryakova, Martin Svoboda, Markus Jaritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosisVanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
Annals of Surgical Oncology|September 10, 2022
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumJacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJacobus Pfisterer, Marie Plante, Ignace Vergote, et al.
JAMA Oncology|October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical TrialIsabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
Pageof 58

Showing results (381-390 of 578) with videos related to

Sort By:
Pageof 58
The Oncologist|September 2, 2018
Prognostic Value of the Progesterone Receptor by Subtype in Patients with Estrogen Receptor-Positive, HER-2 Negative Breast CancerKathleen Van Asten, Laurence Slembrouck, Siel Olbrecht, et al.
Breast (Edinburgh, Scotland)|April 29, 2014
Prediction of non-sentinel lymph node involvement in breast cancer patients with a positive sentinel lymph nodeAnneleen Reynders, Olivier Brouckaert, Ann Smeets, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2020
Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group surveyStefano Greggi, Francesca Falcone, Cono Scaffa, et al.
European Journal of Cancer (Oxford, England : 1990)|January 12, 2023
Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialRenaud Sabatier, Frédérique Rousseau, Florence Joly, et al.
The Lancet. Oncology|May 12, 2019
Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trialIgnace Vergote, Giovanni Scambia, David M O'Malley, et al.
Computational and Structural Biotechnology Journal|May 4, 2019
Interrelations of Sphingolipid and Lysophosphatidate Signaling with Immune System in Ovarian CancerAnastasia Meshcheryakova, Martin Svoboda, Markus Jaritz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 18, 2010
Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosisVanya Van Belle, Ben Van Calster, Olivier Brouckaert, et al.
Annals of Surgical Oncology|September 10, 2022
Impact of BRCA Mutation Status on Tumor Dissemination Pattern, Surgical Outcome and Patient Survival in Primary and Recurrent High-Grade Serous Ovarian Cancer: A Multicenter Retrospective Study by the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) ConsortiumJacek Glajzer, Dan Cacsire Castillo-Tong, Rolf Richter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 13, 2006
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJacobus Pfisterer, Marie Plante, Ignace Vergote, et al.
JAMA Oncology|October 8, 2020
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical TrialIsabelle Ray-Coquard, Philipp Harter, Domenica Lorusso, et al.
Pageof 58